Modality
Radioligand
MOA
CDK4/6i
Target
GLP-1R
Pathway
Innate Imm
NB
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Oct 2030
Phase 3Current
NCT08696939
2,000 pts·NB
2025-04→TBD·Active
NCT03098118
1,340 pts·NB
2018-12→2027-02·Not yet recruiting
NCT07402260
215 pts·NB
2023-09→2030-10·Not yet recruiting
+1 more trial
4,133 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-02-1110mo awayPh3 Readout· NB
2027-04-131.0y awayPh3 Readout· NB
2030-10-074.5y awayPh3 Readout· NB
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Termina…
P3
Not yet…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2027-02-11 · 10mo away
NB
Ph3 Readout
2027-04-13 · 1.0y away
NB
Ph3 Readout
2030-10-07 · 4.5y away
NB
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08696939 | Phase 3 | NB | Active | 2000 | DOR |
| NCT03098118 | Phase 3 | NB | Not yet recr... | 1340 | MRD |
| NCT07402260 | Phase 3 | NB | Not yet recr... | 215 | UPDRS |
| NCT07909843 | Phase 3 | NB | Terminated | 578 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 |